Profil

Caers Jo

Département des sciences cliniques > Hématologie

GIGA I3 - Hematology

See author's contact details
ORCID
0000-0002-3175-1195
Main Referenced Co-authors
Beguin, Yves  (82)
Baron, Frédéric  (45)
Binsfeld, Marilène  (38)
Heusschen, Roy  (33)
Muller, Joséphine  (33)
Main Referenced Keywords
multiple myeloma (21); bone disease (10); Humans (10); Multiple myeloma (7); GVHD (6);
Main Referenced Unit & Research Centers
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège [BE] (13)
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (3)
GIGA I3-Hematology - ULiège [BE] (1)
Giga-Cancer - ULiège [BE] (1)
Giga-Genetics - ULiège [BE] (1)
Main Referenced Disciplines
Hematology (137)
Biochemistry, biophysics & molecular biology (22)
Pharmacy, pharmacology & toxicology (13)
Oncology (7)
General & internal medicine (5)

Publications (total 189)

The most downloaded
28711 downloads
Rajkumar, V., Dimopoulos, M., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., Leleu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., ... San Miguel, J. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 538-548. doi:10.1016/S1470-2045(14)70442-5 https://hdl.handle.net/2268/174646

The most cited

3188 citations (Scopus®)

Rajkumar, V., Dimopoulos, M., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., Leleu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., ... San Miguel, J. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 538-548. doi:10.1016/S1470-2045(14)70442-5 https://hdl.handle.net/2268/174646

Gou, M.-J., Cobraiville, G., Caers, J., & Fillet, M. (28 February 2024). Capillary electrophoresis coupled to ion mobility mass spectrometry to discover surface antigens [Paper presentation]. CE-Forum, Aalen, Germany.
Peer reviewed

Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (15 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. EBMT - EHA 6th European CAR T-cell Meeting, Valence, Spain.

Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (06 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. Séminaire Télévie 2024.

Beguin, C., Kwan, O., Ritacco, C., Debray, J.-C., Dejardin, E., Dubois, S., Köse, M. C., Canti, L., Courtois, J., Seidel, L., Daulne, C., Caers, J., Beguin, Y., Ehx, G., & Baron, F. (17 November 2023). TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease [Paper presentation]. Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France.
Peer reviewed

van de Donk, N. W. C. J., Minnema, M. C., van der Holt, B., Schjesvold, F., Wu, K. L., Broijl, A., Roeloffzen, W. W. H., Gadisseur, A., Pietrantuono, G., Pour, L., van der Velden, V. H. J., Lund, T., Offidani, M., Grasso, M., Giaccone, L., Razawy, W., Tacchetti, P., Mancuso, K., Silkjaer, T., ... Musto, P. (October 2023). Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. The Lancet Oncology, 24 (10), 1119 - 1133. doi:10.1016/S1470-2045(23)00405-9
Peer Reviewed verified by ORBi

Gou, M.-J., Charpentier, J., Cobraiville, G., Crommen, J., Caers, J., & Fillet, M. (October 2023). Improvement of untargeted proteomics workflow for surfaceome profiling and its evaluation through the implementation of quality controls: Application to multiple myeloma. Analytica Chimica Acta, 1279, 341764. doi:10.1016/j.aca.2023.341764
Peer Reviewed verified by ORBi

Chari, A., Askari, E., Caers, J., Costa, L. J., Hilder, B. W., Krishnan, A., Mateos, M.-V., Minnema, M. C., Oriol, A., Pillarisetti, K., van de Donk, N. W. C. J., & Rodríguez-Otero, P. (September 2023). Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncology, 19 (27), 1823 - 1840. doi:10.2217/fon-2023-0332
Peer Reviewed verified by ORBi

Ludwig, H., Terpos, E., van de Donk, N., Mateos, M.-V., Moreau, P., Dimopoulos, M.-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., ... Sonneveld, P. (June 2023). Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology, 24 (6), 255 - e269. doi:10.1016/S1470-2045(23)00159-6
Peer Reviewed verified by ORBi

Gou, M.-J., Charpentier, J., Cobraiville, G., Caers, J., & Fillet, M. (21 May 2023). Improvement of the performance and reliability of a cell-surface untargeted proteomics workflow in the context of multiple myeloma antigen discovery [Poster presentation]. 39th International Symposium on Microscale Separations and Bioanalysis (MSB), Tallahassee, United States.
Peer reviewed

Burniat, A., Noël, A., Colige, A., Vanderplasschen, A., de Kerchove d'Exaerde, A., Kupper Cardozo, A., Van Keymeulen, A., Moens, A., Bondue, A., Herpain, A., Marchant, A., Loumaye, A., Beck, B., Van den Heyden, B., Corvilain, B., Lakaye, B., Rogister, B., Malgrange, B., Michiels, C., ... Brunko, E. (2023). Cent scientifiques répliquent à SEA (Suppression des Expériences sur l’Animal vivant) et dénoncent sa désinformation. La Libre Belgique.

Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Gou, M.-J., Köse, M. C., Nix, C., Cobraiville, G., Caers, J., & Fillet, M. (01 February 2023). Complementarity of CZE-DTIMS-QTOF to microfluidic-RPLC-DTIMS-QTOF for multiple myeloma cells surface antigen discovery [Paper presentation]. CIRM Day, Liège, Belgium.
Peer reviewed

Leleu, X., Katodritou, E., Kuehr, T., Terpos, E., Caers, J., Zambello, R., Brescianini, A., Liang, T., Wetten, S., & Badelita, S. N. (February 2023). Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel. EJHaem, 4 (1), 174 - 183. doi:10.1002/jha2.595
Peer Reviewed verified by ORBi

Charpentier, J., Gou, M.-J., Caers, J., KOSE Murat Cem, & Fillet, M. (01 February 2023). Multiple myeloma cells surface proteomics using microfluidic reverse phase liquid chromatography coupled to drift tube ion mobility quadrupole time-of-flight: optimization of sample preparation protocol and application to patient samples [Paper presentation]. CIRM Day, Liege, Belgium.

Lejeune, M., Köse, M. C., Jassin, M., Gou, M.-J., Herbet, A., Duray, E., Cobraiville, G., FOGUENNE, J., Boquet, D., Gothot, A., Beguin, Y., Fillet, M., & Caers, J. (2023). Integrative Analysis of Proteomics and Transcriptomics Reveals Endothelin Receptor B as Novel Single Target and Identifies New Combinatorial Targets for Multiple Myeloma. HemaSphere, 22, 901. doi:10.1097/HS9.0000000000000901
Peer Reviewed verified by ORBi

CAERS, J., Duray, E., Dumoulin, M., & D’Huyvetter, M. (2023). ANTI-CD38 SINGLE-DOMAIN ANTIBODIES IN DISEASE MONITORING AND TREATMENT.

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., Verona, R., Girgis, S., Yang, S., Goldsmith, R. B., Yao, X., Pillarisetti, K., Hilder, B. W., Russell, J., Goldberg, J. D., & Krishnan, A. (15 December 2022). Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine, 387 (24), 2232-2244. doi:10.1056/NEJMoa2204591
Peer Reviewed verified by ORBi

Köse, M. C., Lejeune, M., Gou, M.-J., Duray, E., Cobraiville, G., Gothot, A., Beguin, Y., Fillet, M., & Caers, J. (15 November 2022). Integrative Analysis of Proteomics and Transcriptomics Reveals the Etrb As Novel Single Target and New Combinatorial Targets for Multiple Myeloma [Paper presentation]. ASH 2022 Symposium, New orleans, United States.

Gou, M.-J., Nix, C., Nys, G., Cobraiville, G., Caers, J., & Fillet, M. (14 November 2022). Capillary electrophoresis and microfluidic-RPLC coupled to ion mobility mass spectrometry as complementary tools to discover surface antigens in multiple myeloma [Paper presentation]. Symposium Advanced analytical technologies for clinical and pharmaceutical applications, Uppsala, Sweden.
Peer reviewed

Gou, M.-J., Köse, M. C., Crommen, J., Nix, C., Cobraiville, G., Caers, J., & Fillet, M. (01 November 2022). Contribution of Capillary Zone Electrophoresis Hyphenated with Drift Tube Ion Mobility Mass Spectrometry as a Complementary Tool to Microfluidic Reversed Phase Liquid Chromatography for Antigen Discovery. International Journal of Molecular Sciences, 23 (21), 13350. doi:10.3390/ijms232113350
Peer Reviewed verified by ORBi

Terpos, E., Zambello, R., Leleu, X., Kuehr, T., Badelita, S. N., Katodritou, E., Brescianini, A., Liang, T., Wetten, S., & Caers, J. (28 October 2022). Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers, 14, 5311. doi:10.3390/cancers14215311
Peer Reviewed verified by ORBi

Gou, M.-J., Köse, M. C., Cobraiville, G., Caers, J., & Fillet, M. (13 September 2022). Use of CE-IM-MS as a complementary tool to microfluidic-LC-IM-MS for cell surface antigen discovery [Paper presentation]. 39th International Symposium of Pharmaceutical and Biomedical analysis (PBA), Mons, Belgium.
Peer reviewed

Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., ... Morgan, G. J. (06 July 2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 3 (4), 273-284. doi:10.1158/2643-3230.BCD-21-0205
Peer reviewed

Gou, M.-J., Cobraiville, G., Nys, G., Caers, J., & Fillet, M. (06 July 2022). Interest of capillary zone electrophoresis coupled to mass spectrometry for clinical proteomics analysis : how to improve sensitivity? [Paper presentation]. 38th International Symposium on Microscale Separations and Bioanalysis, Liège, Belgium.

Gou, M.-J., Cobraiville, G., Caers, J., & Fillet, M. (03 July 2022). Interest of CE-IM-MS as a complementary tool to chromatographic-based methods for cell surface antigen discovery: proof-of-concept using human myeloma LP-1 cell line [Poster presentation]. 38th International Symposium on Microscale Separations and Bioanalysis (MSB 2022), Liège, Belgium.
Peer reviewed

Köse, M. C., Bergiers, I., Malfait, M., Heidrich, B., De Maeyer, D., FOURNEAU, N., Verbist, B., Van Houdt, J., Vanhoof, G., Verona, R., Delforge, M., Depaus, J., Meuleman, N., Van Droogenbroeck, J., Vlummens, P., Heuck, C. J., Bahlis, N., Caers, J., & Casneuf, T. (09 June 2022). S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION [Paper presentation]. EHA symposium, vienna, Austria. doi:10.1097/01.hs9.0000843572.19189.b6

Kegyes, D.* , Constantinescu, C.* , Vrancken, L., Rasche, L., Grégoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (07 June 2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology and Oncology, 15 (1), 78. doi:10.1186/s13045-022-01296-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Roussel, M., Lauwers-Cances, V., Macro, M., Leleu, X., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M.-L., Rigaudeau, S., Dib, M., Nicolas-Virelizier, E., Escoffre-Barbe, M., Belhadj, K., Mariette, C., Stoppa, A.-M., Araujo, C., Doyen, C., ... Attal, M. (05 May 2022). Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 139 (18), 2747-2757. doi:10.1182/blood.2021014635
Peer Reviewed verified by ORBi

Baron, F., Caers, J., & Humblet-Baron, S. (May 2022). Serological response to SARS-CoV-2 mRNA-LNP vaccine in patients with multiple myeloma: a negative impact of CD38(+) Treg? British Journal of Haematology, 197 (4), 391-393. doi:10.1111/bjh.18110
Peer Reviewed verified by ORBi

Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., & Richardson, P. (21 March 2022). Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 12 (3), 45. doi:10.1038/s41408-022-00643-3
Peer Reviewed verified by ORBi

Gou, M.-J., COBRAIVILLE, G., CAERS, J., & Fillet, M. (02 February 2022). Optimization of OPM-2 cell surface protein isolation process for multiple myeloma proteomics using LC-Chip coupled with IM-QTOF [Poster presentation]. 4th CIRM Day, Liege, Belgium.

Caers, J., Duray, E., Vrancken, L., Marcion, G., Bocuzzi, V., De Veirman, K., Krasniqi, A., Lejeune, M., Withofs, N., Devoogdt, N., Dumoulin, M., Karlström, A. E., & D'Huyvetter, M. (2022). Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology, 13, 911080. doi:10.3389/fimmu.2022.911080
Peer Reviewed verified by ORBi

Vekemans, M.-C., Doyen, C., Caers, J., Wu, K., Kentos, A., Mineur, P., Michaux, L., Delforge, M., & Meuleman, N. (2022). Recommendations on the management of multiple myeloma in 2020. Acta Clinica Belgica, 77, 445-461. doi:10.1080/17843286.2020.1860411
Peer Reviewed verified by ORBi

Gou, M.-J., COBRAIVILLE, G., CAERS, J., & Fillet, M. (12 July 2021). Multiple myeloma cells surface proteome analysis using LC-Chip coupled with IM-qTOF: optimization of cell surface protein isolation procedure [Poster presentation]. 37th International Symposium on Microscale Separation and Bioanalysis, Boston, United States.

Ludwig, H., Boccadoro, M., Moreau, P., San-Miguel, J., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T., Driessen, C., Hajek, R., Dimopoulos, M. A., Gay, F., Avet-Loiseau, H., Terpos, E., Zojer, N., Mohty, M., Mateos, M.-V., Einsele, H., Delforge, M., ... Sonneveld, P. (2021). Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 35, 31-44. doi:10.1038/s41375-020-01016-0
Peer Reviewed verified by ORBi

Gamper, E. M., Cottone, F., Sommer, K., Norman, R., King, M., Breccia, M., Caocci, G., Patriarca, A., Palumbo, G. A., Stauder, R., Niscola, P., Platzbecker, U., Caers, J., Vignetti, M., & Efficace, F. (2021). The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 137, 31-44. doi:10.1016/j.jclinepi.2021.03.015
Peer Reviewed verified by ORBi

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1
Peer Reviewed verified by ORBi

Fernández de Larrea, C., Kyle, R., Rosiñol, L., Paiva, B., Engelhardt, M., Usmani, S., Caers, J., Gonsalves, W., Schjesvold, F., Merlini, G., Lentzch, S., Ocio, E., Garderet, L., Moreau, P., Sonneveld, P., Badros, A., Gahrton, G., Goldschmidt, H., Tuchman, S., ... Mateos, M. V. (2021). Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 11 (12), 192. doi:10.1038/s41408-021-00587-0
Peer Reviewed verified by ORBi

Vrancken, L., Lejeune, M., PIROTTE, M., Duray, E., Köse, M. C., BEGUIN, Y., & CAERS, J. (2021). Le myélome multiple : un tour d’horizon des nouveautés dans sa biologie et son traitement. Revue Médicale de Liège, 76, 482-488.
Peer reviewed

Lejeune, M., Duray, E., Peipp, M., Clémenceau, B., Baron, F., Beguin, Y., & Caers, J. (2021). Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 13 (12), 3072. doi:10.3390/cancers13123072
Peer Reviewed verified by ORBi

Bolomsky, A., Miettinen, J. J., Malyutina, A., Besse, A., Huber, J., Fellinger, S., Breid, H., Parsons, A., Klavins, K., Hannich, J. T., Kubicek, S., Caers, J., Hübl, W., Schreder, M., Zojer, N., Driessen, C., Tang, J., Besse, L., Heckman, C. A., & Ludwig, H. (2021). Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Advances, 5 (20), 4125-4139. doi:10.1182/bloodadvances.2020003826
Peer Reviewed verified by ORBi

Duray, E., Lejeune, M., Baron, F., Beguin, Y., Devoogdt, N., Krasniqi, A., Lauwers, Y., Zhao, Y. J., D'Huyvetter, M., Dumoulin, M., & Caers, J. (2021). A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of hematology & oncology, 14 (1), 183. doi:10.1186/s13045-021-01171-6
Peer reviewed

Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M.-A., Dispenzieri, A., Einsele, H., Engelhardt, M., Fernández de Larrea, C., Gahrton, G., Gay, F., Hájek, R., Hungria, V., Jurczyszyn, A., Kröger, N., ... Bladé, J. (2021). Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 194 (3), 496-507. doi:10.1111/bjh.17338
Peer Reviewed verified by ORBi

RADERMECKER, A., BONNET, C., LUTTERI, L., CHAPELLE, A.-C., PETIGNOT, S., LIEVENS, I., & CAERS, J. (2021). Un cas illustratif de syndrome de POEMS. Revue Médicale de Liège, 76, 156-159.
Peer reviewed

Musto, P., Engelhardt, M., Caers, J., Bolli, N., Kaiser, M., Van de Donk, N., Terpos, E., Broijl, A., De Larrea, C. F., Gay, F., Goldschmidt, H., Hajek, R., Vangsted, A. J., Zamagni, E., Zweegman, S., Cavo, M., Dimopoulos, M., Einsele, H., Ludwig, H., ... Miguel, J. S. (2021). 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 106 (11), 2799-2812. doi:10.3324/haematol.2021.278519
Peer Reviewed verified by ORBi

Ludwig, H., Sonneveld, P., Facon, T., San-Miguel, J., Avet-Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., Zweegman, S., Engelhardt, M., Driessen, C., Cook, G., Dimopoulos, M. A., Gay, F., Einsele, H., Delforge, M., Caers, J., ... Terpos, E. (2021). COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology, 8, 934-e946. doi:10.1016/S2352-3026(21)00278-7
Peer Reviewed verified by ORBi

Gou, M.-J., Nys, G., COBRAIVILLE, G., Demelenne, A., Servais, A.-C., CAERS, J., & Fillet, M. (30 September 2020). CE-MS/MS: investigation of two hyphenating approaches for proteomics studies in the context of multiple myeloma [Paper presentation]. 36th International Symposium on Microscale Separations and Bioanalysis, Saint-Malo, France.

Gou, M.-J., Nys, G., COBRAIVILLE, G., Demelenne, A., Servais, A.-C., Caers, J., & Fillet, M. (September 2020). Capillary electrophoresis tandem mass spectrometry for proteomics in the context of multiple myeloma: investigation of two hyphenating approaches [Paper presentation]. 36th International Symposium on Microscale Separations and Bioanalysis.

Lejeune, M., Köse, M. C., Duray, E., Einsele, H., Beguin, Y., & Caers, J. (07 May 2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology, 11 (762), 1-20. doi:10.3389/fimmu.2020.00762
Peer Reviewed verified by ORBi

Lejeune, M., Köse, M. C., Duray, E., Beguin, Y., & CAERS, J. (2020). Les anticorps bispécifiques ciblant les lymphocytes T dans le myélome multiple. OncoHemato : Revue Multidisciplinaire d'Oncologie et Hématologie, 14 (6), 30-34.
Peer reviewed

Vande Catsyne, C.-A., Sayyed, S. A., Molina Ortiz, P., Moës, B., Communi, D., Muller, J., Heusschen, R., CAERS, J., Azzi, A., Erneux, C., & Schurmans, S. (2020). Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. Advances in Biological Regulation, 76, 100651. doi:10.1016/j.jbior.2019.100651
Peer Reviewed verified by ORBi

Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020). MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of hematology & oncology, 13 (1), 173. doi:10.1186/s13045-020-01007-9
Peer reviewed

Caers, J. (2020). Mass cytometry in POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) syndrome: looking for a needle in a haystack. British Journal of Haematology, 190, 16-17. doi:10.1111/bjh.16554
Peer Reviewed verified by ORBi

Bolomsky, A., Muller, J., Stangelberger, K., Lejeune, M., Duray, E., Breid, H., Vrancken, L., Pfeiffer, C., Hübl, W., Willheim, M., Weetall, M., Branstrom, A., Zojer, N., Caers, J., & Ludwig, H. (2020). The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. British Journal of Haematology, 190, 877-890. doi:10.1111/bjh.16595
Peer Reviewed verified by ORBi

Efficace, F., Cottone, F., Oswald, L. B., Cella, D., Patriarca, A., Niscola, P., Breccia, M., Platzbecker, U., Palumbo, G. A., Caocci, G., Stauder, R., Ricco, A., Petranovic, D., Caers, J., Luppi, M., Fianchi, L., Frairia, C., Capodanno, I., Follini, E., ... Vignetti, M. (2020). The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 34, 2451-2459. doi:10.1038/s41375-020-0746-8
Peer Reviewed verified by ORBi

Caers, J. (2020). The Road to a Cure: Emerging Treatments for Multiple Myeloma. Cancers, 12, 3593. doi:10.3390/cancers12123593
Peer Reviewed verified by ORBi

Gamberi, B., Berthou, C., Hernandez, M., Semenzato, G., Tholouli, E., Hájek, R., Caers, J., Dimopoulos, M., Minnema, M. C., Andreasson, B., Parreira, J., Crotty, G., Remes, K., Kueenburg, E., Rosettani, B., Di Micco, A., Peters, S., Bacon, P., & Blau, I. W. (2020). A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 20, 629-e644. doi:10.1016/j.clml.2020.05.006
Peer reviewed

Caocci, G., Vignetti, M., Patriarca, A., Breccia, M., Platzbecker, U., Palumbo, G. A., Stauder, R., Cottone, F., Petranovic, D., Voso, M. T., Tafuri, A., Invernizzi, R., Caers, J., Luppi, M., La Nasa, G., Niscola, P., & Efficace, F. (2020). High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 112, 141-146. doi:10.1007/s12185-020-02920-y
Peer Reviewed verified by ORBi

WITHOFS, N., Beguin, Y., COUSIN, F., Tancredi, T., SIMONI, P., Alvarez-Miezentseva, V., DE PRIJCK, B., HAFRAOUI, K., Bonnet, C., Baron, F., Hustinx, R., & Caers, J. (2019). Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions. Hematological Oncology, 37, 193-201. doi:10.1002/hon.2600
Peer Reviewed verified by ORBi

Nokin, M.-J., Bellier, J., Durieux, F., Peulen, O., Rademaker, G., Gabriel, M., Monseur, C., CHARLOTEAUX, B., Verbeke, L., van Laere, S., RONCARATI, P., Herfs, M., Lambert, C., Scheijen, J., Schalkwijk, C., Colige, A., Caers, J., Delvenne, P., Turtoi, A., ... Bellahcene, A. (2019). Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. Breast Cancer Research, 21(1, 11. doi:10.1186/s13058-018-1095-7
Peer Reviewed verified by ORBi

Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wasch, R., Gay, F., Larocca, A., Offidani, M., Zweegman, S., Terpos, E., Goldschmidt, H., Cavo, M., Ludwig, H., Driessen, C., Auner, H., Caers, J., Gramatzki, M., Dimopoulos, M. A., Boccadoro, M., ... Engelhardt, M. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of Internal Medicine, 286, 63-74. doi:10.1111/joim.12882
Peer Reviewed verified by ORBi

Muller, J., Duray, E., Lejeune, M., DUBOIS, S., Plougonven, E., Léonard, A., Storti, P., Giuliani, N., Cohen-Solal, M., Hempel, U., Thijssen, V., BEGUIN, Y., Heusschen, R., & CAERS, J. (2019). Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts. Cancers, 11 (2), 261. doi:10.3390/cancers11020261
Peer Reviewed verified by ORBi

Bakker, J., Balthazart, J., Baron, F., Beguin, Y., Bettendorff, L., Blanpain, C., Bureau, F., Caers, J., Cani, P., Cataldo, D., Cornil, C., Clercx, C., Cloots, R., Colige, A., Daube, G., De Backer, O., de Kerchove d'Exaerde, A., Desmecht, D., Desmet, C., ... Wittamer, V. (2018). La souris, le patient, et le faux expert. Décryptage d'une mystification. Le Vif. L'Express.

Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M. A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M., & Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 32 (9), 1883-1898. doi:10.1038/s41375-018-0209-7
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Duray, E., WITHOFS, N., Bolomsky, A., Baron, F., Beguin, Y., Menu, E., Ludwig, H., & Caers, J. (2018). Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Leukemia and Lymphoma, 59, 14-28. doi:10.1080/10428194.2017.1323272
Peer Reviewed verified by ORBi

Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397
Peer Reviewed verified by ORBi

Vercruyssen, M., Vrancken, L., & CAERS, J. (2018). What is new in MGUS and smoldering multiple myeloma. Belgian Journal of Hematology, 9, 2-7.
Peer Reviewed verified by ORBi

Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wasch, R., D'Agostino, M., Scheubeck, S., Goldschmidt, H., Gay, F., Cavo, M., Ludwig, H., Straka, C., Bringhen, S., Auner, H. W., Caers, J., Gramatzki, M., Offidani, M., Dimopoulos, M. A., Einsele, H., ... Engelhardt, M. (2018). Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 32, 1697-1712. doi:10.1038/s41375-018-0142-9
Peer Reviewed verified by ORBi

Caers, J., Paiva, B., Zamagni, E., Leleu, X., Blade, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Ocio, E., Delforge, M., Sezer, O., Beksac, M., Ludwig, H., Merlini, G., Zweegman, S., Engelhardt, M., & Rosinol, L. (2018). Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology and Oncology, 11 (1), 10. doi:10.1186/s13045-017-0549-1
Peer Reviewed verified by ORBi

Fostier, K., Caers, J., Meuleman, N., Broos, K., Corthals, J., Thielemans, K., Schots, R., & De Keersmaecker, B. (2018). Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget, 9 (29), 20476-20489. doi:10.18632/oncotarget.24944
Peer Reviewed verified by ORBi

Fostier, K., & CAERS, J. (2018). Diagnosis and monitoring of multiple myeloma patients. Belgian Journal of Hematology, 9, 8-11.
Peer Reviewed verified by ORBi

Vrancken, L., Muller, J., Lejeune, M., Grégoire, C., Delens, L., Jaspers, A., Servais, S., DE PRIJCK, B., Baron, F., Caers, J., & Beguin, Y. (2018). Nouveautes dans la prise en charge du myelome. Revue Médicale Suisse, 14 (615), 1438-1442.
Peer Reviewed verified by ORBi

Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M.-V., Cook, G., Leleu, X., ... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 32, 1542-1560. doi:10.1038/s41375-018-0040-1
Peer Reviewed verified by ORBi

Fank, H., Caers, J., Marot, L., De Montjoye, L., Tennstedt, D., Baeck, M., & Dekeuleneer, V. (2018). Schnitzler syndrome associated with hairy cell leukemia presenting with chronic urticaria and arthralgias. JAAD Case Reports, 4 (4), 386-389. doi:10.1016/j.jdcr.2017.12.012
Peer Reviewed verified by ORBi

Bolomsky, A., Heusschen, R., Schlangen, K., Stangelberger, K., Muller, J., Schreiner, W., Zojer, N., Caers, J., & Ludwig, H. (2018). Maternal embryonic leucine zipper kinase is a novel target for proliferation associated high-risk myeloma. Haematologica, 103, 325-335. doi:10.3324/haematol.2017.172973
Peer Reviewed verified by ORBi

Caers, J., Garderet, L., Kortum, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., ... Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 103, 1172-1184. doi:10.3324/haematol.2018.189159
Peer Reviewed verified by ORBi

Gay, F., Engelhardt, M., Terpos, E., Wasch, R., Giaccone, L., Auner, H. W., Caers, J., Gramatzki, M., van de Donk, N., Oliva, S., Zamagni, E., Garderet, L., Straka, C., Hajek, R., Ludwig, H., Einsele, H., Dimopoulos, M., Boccadoro, M., Kroger, N., ... Sonneveld, P. (2018). From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica, 103, 197-211. doi:10.3324/haematol.2017.174573
Peer Reviewed verified by ORBi

Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., Heusschen, R., De Raeve, H., Schots, R., Vanderkerken, K., Caers, J., & Menu, E. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 8 (11), 105. doi:10.1038/s41408-018-0139-7
Peer Reviewed verified by ORBi

Amorim, C., Andris, F., Arckens, L., Arnould, T., Aron, S., Bakker, J., Balligand, M., Balthazart, J., Baron, F., Beck, B., Beguin, Y., Behets, C., Bellefroid, E., Bertrand, L., Bettendorff, L., Bindels, L., Blankert, B., Blanpain, C., Bondue, A., ... Wittamer, V. (2017). L’expérimentation animale reste indispensable (OPINION). La Libre Belgique.

Heusschen, R., Bolomsky, A., Schlangen, K., Schonfelder, K., Muller, J., Shreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (February 2017). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease [Paper presentation]. 32nd General Annual Meeting of the Belgian Hematological Society.

Wenric, S.* , Sticca, T.* , CABERG, J.-H., Josse, C., Fasquelle, C., HERENS, C., JAMAR, M., MAX, S., GOTHOT, A., CAERS, J., & Bours, V. (2017). Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample. Genetic Epidemiology, 41, 35-40. doi:10.1002/gepi.22019
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Hillengass, J., Moulopoulos, L. A., Delorme, S., Koutoulidis, V., Mosebach, J., Hielscher, T., Drake, M., Rajkumar, S. V., Oestergaard, B., Abildgaard, N., Hinge, M., Plesner, T., Suehara, Y., Matsue, K., Waage, A., Goldschmidt, H., Dimopoulos, M. A., Lentzsch, S., Durie, B., ... CAERS, J. (2017). Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer Journal, 7 (8), 599. doi:10.1038/bcj.2017.78
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., WITHOFS, N., BARON, F., BEGUIN, Y., & CAERS, J. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Belgian Journal of Hematology, 8, 66-74.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Bolomsky, A., Schonfelder, K., Plougonven, E., Léonard, A., BEGUIN, Y., Cohen-Solal, M., Heinz, L., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) inhibition has direct effects on bone cells and prevents the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 44th Annual European Calcified Tissue Society Congress.

Heusschen, R., Muller, J., Bolomsky, A., Ludwig, H., & CAERS, J. (2017). Maternal Embryonic Leucine Zipper Kinase (MELK) is a key player and an attractive novel target in proliferation-associated high risk multiple myeloma [Paper presentation]. Meeting of the Austrian Society for Hematology and Oncology 2017.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

WITHOFS, N., COUSIN, F., DE PRIJCK, B., Bonnet, C., Hustinx, R., Gambhir, S. S., Beguin, Y., & Caers, J. (2017). A First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma. Contrast Media and Molecular Imaging, 2017, 6162845. doi:10.1155/2017/6162845
Peer Reviewed verified by ORBi

Sticca, T., CABERG, J.-H., Wenric, S., Poulet, C., HERENS, C., JAMAR, M., Josse, C., El Guendi, S., MAX, S., BEGUIN, Y., GOTHOT, A., CAERS, J., & Bours, V. (2017). Genomic Studies of Multiple Myeloma Reveal an Association between X Chromosome Alterations and Genomic Profile Complexity. Genes, Chromosomes and Cancer, 56, 18-27. doi:10.1002/gcc.22397
Peer Reviewed verified by ORBi

Vekemans, M.-C., Beel, K., CAERS, J., Meuleman, N., Bries, G., Demuynck, H., DE PRIJCK, B., De Samblanx, H., Deweweirea, A., Fostier, K., Mineur, P., Vaes, M., Vande Broeck, I., Vande Velde, A., Van Droogenbroeck, J., Vlummers, P., Wu, K.-L., Schots, R., Delforge, M., & Doyen, C. (2017). Update on therapy of relapsed and refractory multiple myeloma. Belgian Journal of Hematology, 8, 53-65.
Peer Reviewed verified by ORBi

SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients [Paper presentation]. 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium.

Jurczyszyn, A., Olszewska-Szopa, M., Hungria, V., Crusoe, E., Pika, T., Delforge, M., Leleu, X., Rasche, L., Nooka, A., Druzd-Sitek, A., Walewski, J., Davila, J., CAERS, J., Maisnar, V., Gertz, M., Gentile, M., Fantl, D., Mele, G., Vesole, D., ... Castillo, J. (September 2016). Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 57 (9 2071-6), 2071-6. doi:10.3109/10428194.2015.1128542
Peer Reviewed verified by ORBi

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

WITHOFS, N., COUSIN, F., TANCREDI, T., SIMONI, P., DE PRIJCK, B., HAFRAOUI, K., BONNET, C., HUSTINX, R., BEGUIN, Y., & CAERS, J. (14 June 2016). Comparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions [Paper presentation]. SNMMI 2016 Annual Meeting.

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., CAERS, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H., Streetly, M., Ludwig, H., Mellqvist, U., Chng, W., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, J., ... Richardson, P. (30 May 2016). Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. Leukemia, 30 (5), 1005-1017. doi:10.1038/leu.2015.356
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K., Chng, W.-J., Moreau, P., Attal, M., Kyle, R., CAERS, J., Hillengass, J., San Miguel, J., van de Donk, N., Einsele, H., Bladé, J., Durie, B., Goldschmidt, H., Mateos, M.-V., ... Orlowski, R. (2016). Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 127 (24), 2955-62. doi:10.1182/blood-2016-01-631200
Peer Reviewed verified by ORBi

Bolomsky, A., Heusschen, R., Schlangen, K., Schönfelder, K., Muller, J., Schreiner, W., Zojer, N., CAERS, J., & Ludwig, H. (2016). Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma. Blood.
Peer Reviewed verified by ORBi

CAERS, J., de Larrea, C., Leleu, X., Heusschen, R., Zojer, N., Decaux, O., Kastritis, E., Minnema, M., Jurczyszyn, A., Beguin, Y., Wäsch, R., Palumbo, A., Dimopoulos, M., Mateos, M. V., Ludwig, H., & Engelhardt, M. (2016). The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 21, 333-342. doi:10.1634/theoncologist.2015-0303
Peer Reviewed verified by ORBi

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., BEGUIN, Y., Poirier, F., Cohen-Solal, M., Thijssen, V., & CAERS, J. (2016). Galectin-1 attenuates bone resorption by osteoclasts [Poster presentation]. EMBO Workshop: Transducing glycan information into function: Lessons from galectins.

Binsfeld, M., Muller, J., Lamour, V., De Veirman, K., De Raeve, H., Bellahcene, A., Van Valckenborgh, E., BARON, F., BEGUIN, Y., CAERS, J., & Heusschen, R. (2016). Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget, 7, 37931-37943. doi:10.18632/oncotarget.9270
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma [Poster presentation]. GIGA day 2016, Liège, Belgium.

Heusschen, R., Muller, J., Fillet, M., Vanderkerken, K., Thijssen, V., Cohen-Solal, M., BEGUIN, Y., & CAERS, J. (2016). Lectin-glycoprotein interactions in the diagnosis and biology of myeloma-related bone disease [Poster presentation]. 2nd Herbert Fleisch Workshop of the International Bone and Mineral Society, Brugge, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Jurczyszyn, A., Grzasko, N., Gozzetti, A., Czepiel, J., Cerase, A., Hungria, V., Crusoe, E., Silva Dias, A. L. M., Vij, R., Fiala, M. A., CAERS, J., Rasche, L., Nooka, A. K., Lonial, S., Vesole, D. H., Philip, S., Gangatharan, S., Druzd-Sitek, A., Walewski, J., ... Castillo, J. J. (2016). Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 91 (6), 575-80. doi:10.1002/ajh.24351
Peer Reviewed verified by ORBi

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

WITHOFS, N., NANNI, C., SIMONI, P., FANTI, S., BEGUIN, Y., & CAERS, J. (20 March 2015). Imaging myeloma and related monoclonal plasma cell disorders using MRI, low dose whole-body CT and FDG PET/CT. Clinical and Translational Imaging, 3, 95-109. doi:10.1007/s40336-015-0119-x
Peer reviewed

BINSFELD, M., Hannon, M., Humblet-Baron, S., Beguin, Y., Baron, F., & CAERS, J. (30 January 2015). Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models [Poster presentation]. 30th General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Thijssen, V., Heusschen, R., CAERS, J., & Griffioen, A. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochimica et Biophysica Acta - Reviews on Cancer, 1855 (2), 235-47. doi:10.1016/j.bbcan.2015.03.003
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood.
Peer Reviewed verified by ORBi

Binsfeld, M., HANNON, M., Otjacques, E., Humblet-Baron, S., BAUDOUX, E., BEGUIN, Y., BARON, F., & CAERS, J. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy, 64, 989-998. doi:10.1007/s00262-015-1708-2
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.
Peer Reviewed verified by ORBi

Tangen, J.-M., Tierens, A., CAERS, J., BINSFELD, M., Olstad, O. K., Troseid, A.-M. S., Wang, J., Tjonnfjord, G. E., & Hetland, G. (January 2015). Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. BioMed Research International, 2015, 718539. doi:10.1155/2015/718539
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma. Blood, 126 (23), 3018.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Plougonven, E., Mahli, N., Carmeliet, G., Léonard, A., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2015). The SRC inhibitor AZD0530 prevents the development of osteolytic bone disease in multiple myeloma [Poster presentation]. 57th ASH Annual Meeting and Exposition, Orlando, United States - Florida.

Sticca, T., Wenric, S., CABERG, J.-H., MAX, S., GOTHOT, A., CAERS, J., & Bours, V. (2015). Genomic study of multiple myeloma based on SNP-aCGH and high-throughput exome sequencing.

CAERS, J., WITHOFS, N., Hillengass, J., SIMONI, P., Zamagni, E., HUSTINX, R., & BEGUIN, Y. (April 2014). The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma. Haematologica, 99 (4), 629-37. doi:10.3324/haematol.2013.091918
Peer Reviewed verified by ORBi

CAERS, J., HAFRAOUI, K., KEUTGENS, A., CABERG, J.-H., LAMBERT, F., TASSIN, F., & BEGUIN, Y. (02 February 2014). Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. European Journal of Haematology, 92 (2), 179-180. doi:10.1111/ejh.12233
Peer Reviewed verified by ORBi

Binsfeld, M., Fostier, K., Muller, J., Baron, F., Schots, R., Beguin, Y., Heusschen, R., & CAERS, J. (2014). Cellular immunotherapy in multiple myeloma : lessons from preclinical models. Biochimica et Biophysica Acta - Reviews on Cancer, 1846, 392-404. doi:10.1016/j.bbcan.2014.08.001
Peer Reviewed verified by ORBi

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764
Peer Reviewed verified by ORBi

Rajkumar, V., Dimopoulos, M., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., Leleu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., ... San Miguel, J. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 538-548. doi:10.1016/S1470-2045(14)70442-5
Peer Reviewed verified by ORBi

Heusschen, R., Schulkens, I., Muller, J., Griffoen, A., Beguin, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades. International Journal of Molecular Medicine.
Peer Reviewed verified by ORBi

Heusschen, R., Muller, J., Binsfeld, M., Thijssen, V., BEGUIN, Y., & CAERS, J. (2014). Galectin expression in the multiple myeloma microenvironment [Poster presentation]. GIGA day 2014, Liège, Belgium.

CAERS, J., Binsfeld, M., Muller, J., Heusschen, R., & Beguin, Y. (2014). Gammapathie monoclonale de signification indéterminée : information destinée aux médecins référents. Revue Médicale de Liège, 69, 41-46.
Peer reviewed

Heusschen, R., Schulkens, I., Muller, J., Griffioen, A., BEGUIN, Y., Thijssen, V., & CAERS, J. (2014). Galectins in cancer: jacks of all trades [Paper presentation]. 19th World Congress on Advances in Oncology, Athens, Greece.

CAERS, J., & BEGUIN, Y. (2014). Le myélome multiple asymptomatique : le paysage thérapeutique change. Oncol. Hematol, 8, 39-45.
Peer reviewed

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology.

Muller, J., CAERS, J., Binsfeld, M., Dubois, S., Carmeliet, G., BEGUIN, Y., & Heusschen, R. (2014). Galectin expression in the multiple myeloma microenvironment. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Binsfeld, M., Heusschen, R., Lamour, V., Van Valckenborgh, E., Bellahcene, A., Baron, F., BEGUIN, Y., & CAERS, J. (2014). Multiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines. Belgian Journal of Hematology.

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.
Peer Reviewed verified by ORBi

CAERS, J., Vekemans, M.-C., Bries, G., Beel, K., Delrieu, V., Deweweire, A., Demuynck, H., DE PRIJCK, B., De Samblanx, H., Kentos, A., Meuleman, N., Mineur, P., Offner, F., Vande Broek, I., Van Droogenbroeck, J., Vande Velde, A., Wu, K.-L., Delforge, M., Schots, R., & Doyen, C. (September 2013). Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Annals of Medicine, 45, 413-422. doi:10.3109/07853890.2013.801562
Peer Reviewed verified by ORBi

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland.

Fernández de Larrea, C., Kyle, R., Durie, B., Ludwig, H., Usmani, S., Vesole, D., Hajek, R., San Miguel, J., Sezer, O., Schots, R., Sonneveld, P., Kumar, S., Mahindra, A., Comenzo, R., Palumbo, A., Anderson, K., Richardson, P., Badros, A., CAERS, J., ... Shah, J. (April 2013). Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 27 (4), 780-91. doi:10.1038/leu.2012.336
Peer Reviewed verified by ORBi

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.
Peer Reviewed verified by ORBi

JASPERS, A., CAERS, J., LE GAC, G., FEREC, C., BEGUIN, Y., & FILLET, G. (February 2013). A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA). British Journal of Haematology, 160 (4), 564-565. doi:10.1111/bjh.12147
Peer Reviewed verified by ORBi

Bonnet, C., MENTEN, C., LAMBERT, F., Gothot, A., Baron, F., CAERS, J., HERENS, C., & Beguin, Y. (25 January 2013). Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones [Poster presentation]. BHS, General Annual Meeting.

Otjacques, E., Binsfeld, M., Beguin, Y., Noël, A., Cataldo, D., & CAERS, J. (2013). Aspects biologiques de l'angiogenèse dans le myélome multiple. Oncohématologie, 7 (2), 6-12.
Peer reviewed

DE PASQUAL, A., BIESSAUX, Y., Blettard, N., CREMERS, S., & CAERS, J. (2013). Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis. Acta Clinica Belgica, 68 (4), 303-305. doi:10.2143/ACB.3268
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States.

Otjacques, E., Binsfeld, M., Rocks, N., Blacher, S., Vanderkerken, K., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2013). Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. PLoS ONE, 8 (5), 62818. doi:10.1371/journal.pone.0062818
Peer Reviewed verified by ORBi

Cornet, G., GRAYET, B., Godon, A., & CAERS, J. (January 2013). Image of the month: Hairy kidneys. Revue Médicale de Liège, 68 (1), 4-5.
Peer reviewed

Haroche, J., Arnaud, L., Cohen-Aubart, F., Hervier, B., Saadoun, D., Costedoat-Chalumeau, N., Besnard, S., Heang Ly, K., Pavic, M., Fuzibet, J.-G., Raffray, L., Aaron, L., Bindi, P., Marinho, A., Blomberg, B., Salvatierra, J., Dechant, C., Rigolet, A., Lifermann, F., ... Amoura, Z. (2013). Erdheim-Chester Disease : A Monocentric Series Of 96 Patients [Poster presentation]. 2013 ACR/ARHP Annual Meeting.

Vekemans, M.-C., CAERS, J., Doyen, C., & Michaux, L. (2013). Gammapathies monoclonales de signification indéterminée. Louvain Medical, 132 (2), 51-62.
Peer reviewed

SIMONI, P., STULKO, J., BEN MUSTAPHA, S., SCHOYSMAN, L., BIANCHI, E., WITHOFS, N., RACARU, T., CAERS, J., & ALVAREZ MIEZENTSEVA, V. (2013). Bone mass of the calvarium. Skeletal Radiology, 42, 1185-1187. doi:10.1007/s00256-012-1547-6
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society.

HAFRAOUI, K., CAERS, J., TASSIN, F., & Beguin, Y. (2013). Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide [Poster presentation]. BHS 28th General Annual Meeting, Gent, Belgium.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1.
Peer Reviewed verified by ORBi

Gamberi, B., Kyriakou, C., Ashcroft, J., Hernandez, M., CAERS, J., Bos, G., Echeveste, M. A., Berthou, C., Zambello, R., Kuenburg, E., Rosettani, B., Ryder-Smith, B., & Blau, I. (2012). Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM) [Poster presentation]. 54th ASH Annual Meeting.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

Malaise, O., FRUSCH, N., BECK, E., Servais, S., BETEA, D., CAERS, J., DE PRIJCK, B., & BEGUIN, Y. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Leukemia and Lymphoma, 53 (12), 2515-16.
Peer Reviewed verified by ORBi

Hofgaard, P., Jodal, H., Bommert, K., Huard, B., CAERS, J., Carlsen, H., Schwarzer, R., Schunemann, Jundt, F., Lindeberg, M., & Bogen, B. (2012). A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS ONE, 7 (12), 51892. doi:10.1371/journal.pone.0051892
Peer Reviewed verified by ORBi

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).
Peer Reviewed verified by ORBi

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

CAERS, J., BONNET, C., GRAUX, C., DE PRIJCK, B., & BEGUIN, Y. (2011). Prise en charge actuelle des syndromes myélodysplasiques. Revue Médicale Suisse, 7, 1634-1643.
Peer Reviewed verified by ORBi

Otjacques, E., Binsfeld, M., Noël, A., Beguin, Y., Cataldo, D., & CAERS, J. (2011). Biological aspects of angiogenesis in multiple myeloma. International Journal of Hematology, 94 (6), 505-18. doi:10.1007/s12185-011-0963-z
Peer Reviewed verified by ORBi

Bonnet, C., CAERS, J., DE PRIJCK, B., HAFRAOUI, K., & Beguin, Y. (2011). Lymphome du manteau : prise en charge 2011. Revue Médicale Suisse, 7, 1644-1649.
Peer Reviewed verified by ORBi

Segner, S., Theate, I., Poire, X., Tennstedt, D., Marot, & Caers, J. (2010). Diffuse xanthomatosis as a presenting feature of multiple myeloma. European Journal of Haematology, 84, 460-461. doi:10.1111/j.1600-0609.2009.01400.x
Peer Reviewed verified by ORBi

Caers, J., Hose, D., Kuijpers, I., Bos, T., Van Valckenborgh, E., Menu, E., De Bruyne, E., Goldschmidt, H., Van Camp, B., Klein, B., & Vanderkerken, K. (2010). Thymosin Beta 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica, 95 (1), 163-167. doi:10.3324/haematol.2009.006411
Peer Reviewed verified by ORBi

Sinapi, I., Caers, J., Connerotte, T., Koutaissoff, S., & Lambert, M. (2010). Retroperitoneal fibrosis and multiple myeloma: fortuitous association? Revue de Médecine Interne, 31 (5), 4-6. doi:10.1016/j.revmed.2009.04.011
Peer Reviewed verified by ORBi

Caers, J., Otjacques, E., Hose, D., Klein, B., & Vanderkerken, K. (2010). Thymosin beta4 in multiple myeloma: friend or foe. Annals of the New York Academy of Sciences, 1194 (1), 125-130. doi:10.1111/j.1749-6632.2010.05470.x
Peer Reviewed verified by ORBi

Schots, R., Delforge, M., André, M., Bries, G., CAERS, J., Demuynck, H., DE PRIJCK, B., De Samblanx, H., Kentos, A., Meuleman, N., Offner, F., Vekemans, M., Vande Broek, I., Van Droogenbroeck, J., Van de Velde, A., Wu, K., & Doyen, C. (2010). The Belgian 2010 consensus recommendations for the treatment of multiple myeloma. Acta Clinica Belgica, 65, 252-264. doi:10.1179/acb.2010.055
Peer Reviewed verified by ORBi

Bieghs, L., Caers, J., De Bruyne, E., Van Valckenborgh, E., Hibbinbotham, F., Vanderkerken, K., & Menu, E. (2010). The effects of forodesine in murine and human multiple myeloma cells. Advances in Hematology, 2010:131895. doi:10.1155/2010/131895
Peer Reviewed verified by ORBi

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x
Peer Reviewed verified by ORBi

CAERS, J. (2009). New biological and therapeutical findings in the interactions between multiple myeloma cells and their microenvironment [Doctoral thesis, VUB - Vrije Universiteit Brussel]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/257441

CAERS, J. (2009). New biological and therapeutical findings in the interactions between multiple myeloma cells and their microenvironment. Brussels, Belgium: VUBPRESS.

Caers, J., Vande Broek, I., De Raeve, H., Michaux, L., Trullemans, F., Schots, R., Van Camp, B., & Vanderkerken, K. (2008). Multiple Myeloma, an update on diagnosis and treatment. European Journal of Haematology, 81 (5), 329-343. doi:10.1111/j.1600-0609.2008.01127.x
Peer Reviewed verified by ORBi

Caers, J., De Raeve, H., Lepage, D., Van Valckenborgh, E., Menu, E., Alvarez, E., Van Camp, B., & Vanderkerken, K. (2008). Antitumor and anti-angiogenic effects of aplidin in the 5T33MM model, syngeneic model of multiple myeloma. British Journal of Cancer, 98 (12), 1966-74. doi:10.1038/sj.bjc.6604388
Peer Reviewed verified by ORBi

CAERS, J., Hose, D., Kuipers, I., Bos, T., Van Valckenborgh, E., Menu, E., De Bruyne, E., Goldschmidt, H., Van Camp, B., Klein, B., & Vanderkerken, K. (2008). Decreased Thymosin Beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma [Poster presentation]. 50th ASH Annual Meeting.

Caers, J., Van Valckenborgh, E., Menu, E., Van Camp, B., & Vanderkerken, K. (2008). Unraveling the biology of MM disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bulletin du Cancer, 95 (3), 301-13. doi:10.1684/bdc.2008.0600
Peer Reviewed verified by ORBi

Caers, J., Deleu, S., Belaid, Z., De Raeve, H., Van Valckenborgh, E., De Bruyne, E., Defresne, M.-P., Van Riet, I., Van Camp, B., & Vanderkerken, K. (July 2007). Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia, 21 (7), 1580-1584. doi:10.1038/sj.leu.2404658
Peer Reviewed verified by ORBi

CAERS, J., DeLeu, S., Belaid, Z., De Raeve, H., Van Valckenborgh, E., De Bruyne, E., Defresne, M.-P., Van Riet, I., Van Camp, B., & Vanderkerken, K. (2007). Neighboring adipocytes participate in the bone marrow micro-environment of multiple myeloma cells. Leukemia, 21 (7), 1580-4.
Peer Reviewed verified by ORBi

Vanderkerken, K., Van Valckenborgh, E., Menu, E., De Raeve, H., Van Riet, I., Schots, R., CAERS, J., & Van Camp, B. (2007). De bijdrage van muismodellen bij studies naar multipel myeloom. Nederlands Tijdschrift voor Hematologie, 4 (4), 193-143.
Peer reviewed

Caers, J., Günthert, U., De Raeve, H., Van Valckenborgh, E., Menu, E., Van Riet, I., Van Camp, B., & Vanderkerken, K. (2006). The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. British Journal of Haematology, 132 ((4)), 469-77. doi:10.1111/j.1365-2141.2005.05886.x
Peer Reviewed verified by ORBi

Caers, J., Peeters, P., Vanden Houte, K., Van der Niepen, P., & Verbeelen, D. (2006). Acute interstitial nephritis associated with salmonellosis. European Journal of Internal Medicine, 17 (3), 217-9. doi:10.1016/j.ejim.2005.09.026
Peer Reviewed verified by ORBi

Caers, J., & Vanderkerken, K. (2006). Ac-SDKP: linking cardiac remodelling to haematological malignancies. Leukemia and Lymphoma, 47 (9), 1732-3.
Peer Reviewed verified by ORBi

CAERS, J., Belaid, Z., Deleu, S., Defresne, M.-P., & Vanderkerken, K. (2006). Bone Marrow Adipocytes Influence Multiple Myeloma Development by Secretion of Different Growth Factors and Chemokines [Poster presentation]. 48th ASH Annual Meeting.

De Bruyne, E., Andersen, T. L., De Raeve, H., Van Valckenborgh, E., Caers, J., Van Camp, B., Delaisse, J. M., Van Riet, I., & Vanderkerken, K. (2006). Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia, 20 (10), 1870-9. doi:10.1038/sj.leu.2404343
Peer Reviewed verified by ORBi

Caers, J., Asosingh, K., Van Camp, B., Van Riet, I., & Vanderkerken, K. (2005). Of mice and men: disease models of multiple myeloma. Drugs Discovery Today: disease models, 1 (4), 373-380.
Peer reviewed

Caers, J., Fontaine, C., Vinh-Hung, V., De Mey, J., Ponnet, G., Oost, C., Lamote, J., De Greve, J., Van Camp, B., & Lacor, P. (2005). Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Supportive Care in Cancer, 13 ((5)), 325-31. doi:10.1007/s00520-004-0723-1
Peer Reviewed verified by ORBi

CAERS, J., De Raeve, H., Asosingh, K., Van Riet, I., Van Camp, B., & Vanderkerken, K. (17 September 2004). Expression of osteopontin and its receptor the alphavbeta3 integrin in the 5TMM myeloma model [Poster presentation]. Progress against tumor progression, Genoa, Italy.

Caers, J., Reekmans, A., Jochmans, K., Naegels, S., Mana, F., Urbain, D., & Reynaert, H. (2003). Factor V inhibitor after injection of human thrombin in a bleeding ulcer. Endoscopy, 35 ((6)), 542-4. doi:10.1055/s-2003-39678
Peer Reviewed verified by ORBi

Contact ORBi